Q-omics provides the consensus-scored IL5RA profile across patient tissues and cancer cell-line models. IL5RA expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL5RA is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, IL5RA RNA expression shows 14,442 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where IL5RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL5RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL5RA survival associations across molecular data types. IL5RA RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL5RA RNA expression–survival associations across cancer types. High IL5RA expression shows unfavorable associations in KICH, but favorable associations in HNSC, BRCA, SARC, SKCM and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IL5RA RNA expression.
This table summarizes IL5RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL5RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL5RA shows lower tumor expression in KIRC, BLCA, LUAD, COAD, LUSC and KICH. The KIRC box plot shows higher IL5RA RNA expression in normal versus tumor tissue (log2 FC = −0.335, t-test p < 0.001).
This table shows molecular features associated with IL5RA in patient tissues and cancer cell lines. In patient samples, IL5RA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL5RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
